

# NF-kappa B Inhibitors – Pipeline Insight, 2020

<https://marketpublishers.com/r/NC4659331E89EN.html>

Date: November 2020

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: NC4659331E89EN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "NF-kappa B Inhibitors – Pipeline Insight, 2020," report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### NF-kappa B Inhibitors Understanding

#### NF-kappa B Inhibitors: Overview

The nuclear factor- $\kappa$ B (NF- $\kappa$ B) signaling pathway plays a major role in the development, maintenance, and progression of most chronic diseases. NF- $\kappa$ B controls the expression of genes involved in a number of physiological responses, including immune inflammatory responses, acute-phase inflammatory responses, oxidative stress responses, cell adhesion, differentiation, and apoptosis. Recent studies have suggested that NF- $\kappa$ B dysregulation is associated with many diseases including AIDS, atherosclerosis, asthma, arthritis, diabetes, inflammatory bowel disease, stroke, muscle wasting and viral infections. Mounting evidence indicates that NF- $\kappa$ B acts as a link between inflammation and cancer progression, making NF- $\kappa$ B essential to and a potential drug target in hematological malignancies and solid tumors. NF- $\kappa$ B was first

identified in 1986 by Sen and Baltimore in the nucleus bound to an enhancer element of the immunoglobulin kappa light chain gene in B cells. It is now known to be ubiquitous in nature present in all the cell types and is evolutionary conserved. It belongs to the family of Rel proteins that includes c-Rel, RelA (p65), RelB, NF- $\kappa$ B1 (p50 and its precursor p105), and NF- $\kappa$ B2 (p52 and its precursor p100) all of which can form hetero- or homodimers.

## NF-kappa B Inhibitors Emerging Drugs Chapters

This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## NF-kappa B Inhibitors Emerging Drugs

### AMG 0101: AnGes MG

AMG 0101 is being developed by AnGes MG for the treatment of Atopic dermatitis. It is currently in phase III stage of development.

### CXA-10: Complexa

CXA-10 is an oral nitrated fatty acid compound that acts through a constellation of actions including:

Upregulation of Nrf2 pathways, a key pro-reparative and metabolic pathway

Inhibition of NF-Kappa B and TLR4, key drivers of inflammatory molecules and pathways

Inhibition of Xanthine Oxidoreductase, a key intracellular producer of Reactive Oxygen Species add that result in cellular oxidative stress

Increasing the expression of heat shock proteins, which act as chaperones during cellular stress to restore cellular homeostatic mechanisms

## ACT001: Accendatech

ACT001 is an investigational product currently finished testing in phase I clinical studies. ACT001 is a drug designed and developed by Accendatech specifically used to target brain tumor for treatment of GBM and DIPG.

Further product details are provided in the report.....

## NF-kappa B Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in NF-kappa B Inhibitors

There are approx. 90+ key companies which are developing the therapies based on NF-kappa B Inhibitors. The companies which have their drug candidate based on NF-kappa B Inhibitors in the most advanced stage, i.e. phase III include AnGes MG and others

### Phases

DelveInsight's report covers around 90+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### NF-kappa B Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NF-kappa B Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

In October 2020, Catabasis has stopped development of edasalonexent as phase III PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo.

In October 2019, The Company's lead candidate, CXA-10, received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).

## NF-kappa B Inhibitors Report Insights

NF-kappa B Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

NF-kappa B Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

What are the current treatment options available based on the NF-kappa B Inhibitors?

How many companies are developing therapies by working on NF-kappa B Inhibitors?

What are the principal therapies developed by these companies in the industry?

How many therapies are developed by each company for NF-kappa B Inhibitors to treat disease condition?

How many emerging therapies are in early-stage, mid-stage, and late stage of development for NF-kappa B Inhibitors?

Out of total pipeline products, how many therapies are given as a monotherapy

and in combination with other treatments?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NF-kappa B Inhibitors therapies?

Which are the dormant and discontinued products and the reasons for the same?

What is the unmet need for current therapies developed based on this mechanism of action?

What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for NF-kappa B Inhibitors and their status?

What are the results of the clinical studies and their safety and efficacy?

What are the key designations that have been granted for the emerging therapies for NF-kappa B Inhibitors?

How many patents are granted and pending for the emerging therapies of NF-kappa B Inhibitors?

## Key Players

AnGes MG

Complexa

Accendatech

Serenex

OncoViRx

Novo Nordisk

Profectus Biosciences

Mitsubishi Tanabe Pharma

ImmuneTarget

Merck Serono

EntreChem

Link Health Group

#### Key Products

AMG 0101

CXA-10

ACT001

Research programme: NF-kappa B inhibitors

Research programme: I-kappa B kinase/NF-kappa B inhibitors

Research programme: NF-kappa-B pathway inhibitors

IT 901

AS 602868

EC 70124

LH 025



## Contents

Introduction

Executive Summary

NF-kappa B Inhibitors: Overview

Structure

Mechanism of Action

Classification

Application

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

NF-kappa B Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

NF-kappa B Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value

Trends

NF-kappa B Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

AMG 0101: AnGes MG

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

CXA-10: Complexa

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis  
ACT001: Accendatech  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Pre-clinical and Discovery Stage Products  
Comparative Analysis  
Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Inactive Products  
Comparative Analysis  
NF-kappa B Inhibitors Key Companies  
NF-kappa B Inhibitors Key Products  
NF-kappa B Inhibitors- Unmet Needs  
NF-kappa B Inhibitors- Market Drivers and Barriers  
NF-kappa B Inhibitors- Future Perspectives and Conclusion  
NF-kappa B Inhibitors Analyst Views  
NF-kappa B Inhibitors Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for NF-kappa B Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for NF-kappa B Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: NF-kappa B Inhibitors – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/NC4659331E89EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NC4659331E89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970